Source:http://linkedlifedata.com/resource/pubmed/id/19883776
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
2010-2-15
|
| pubmed:abstractText |
A specific predictor during routine follow-up to ascertain risk for postautologous peripheral blood hematopoietic stem cell transplantation (post-APHSCT) relapse in non-Hodgkin lymphoma (NHL) has not been identified. Thus, we studied if new-onset lymphopenia measured by the absolute lymphocyte count (ALC) was a marker of post-APHSCT NHL relapse. ALC was obtained at the time of confirmed relapse, and at last follow-up with no relapse. From 1993 until 2005, 269 patients treated with APHSCT for diffuse large B-cell lymphoma (DLBCL) were included in this study. Patients at last follow-up without relapse (N=137) had a higher ALC compared with those with low ALC at the time of confirmed relapsed (N=132) (median ALC x10(9)/L of 1.66 versus 0.71, P < .0001, respectively). ALC at follow-up was a strong predictor for relapse with an area under the curve (AUC)=0.86 (P < .0001). An ALC <1.0 x 10(9)/L at the time of confirmed relapse had a positive predictive value of 89% and a positive likelihood ratio of 8.4 to predict relapse post-APHSCT. Patients with an ALC > or =1.0 x 10(9)/L (N=147) had a cumulative incidence of relapse of 19% versus 92%, with an ALC <1.0 x 10(9)/L (N=122) (P < .0001). This study suggests that new-onset lymphopenia measured by ALC can be used as marker to assess risk of DLBCL relapse during routine follow-up for after APHSCT.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Mar
|
| pubmed:issn |
1523-6536
|
| pubmed:author | |
| pubmed:copyrightInfo |
Copyright (c) 2010 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.
|
| pubmed:issnType |
Electronic
|
| pubmed:volume |
16
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
376-83
|
| pubmed:meshHeading |
pubmed-meshheading:19883776-Adolescent,
pubmed-meshheading:19883776-Adult,
pubmed-meshheading:19883776-Aged,
pubmed-meshheading:19883776-Area Under Curve,
pubmed-meshheading:19883776-Biological Markers,
pubmed-meshheading:19883776-Confounding Factors (Epidemiology),
pubmed-meshheading:19883776-Female,
pubmed-meshheading:19883776-Humans,
pubmed-meshheading:19883776-L-Lactate Dehydrogenase,
pubmed-meshheading:19883776-Logistic Models,
pubmed-meshheading:19883776-Lymphocyte Count,
pubmed-meshheading:19883776-Lymphoma, Large B-Cell, Diffuse,
pubmed-meshheading:19883776-Lymphopenia,
pubmed-meshheading:19883776-Male,
pubmed-meshheading:19883776-Middle Aged,
pubmed-meshheading:19883776-Peripheral Blood Stem Cell Transplantation,
pubmed-meshheading:19883776-Predictive Value of Tests,
pubmed-meshheading:19883776-Proportional Hazards Models,
pubmed-meshheading:19883776-Recurrence,
pubmed-meshheading:19883776-Retrospective Studies,
pubmed-meshheading:19883776-Risk,
pubmed-meshheading:19883776-Risk Factors,
pubmed-meshheading:19883776-Transplantation, Autologous,
pubmed-meshheading:19883776-Young Adult
|
| pubmed:year |
2010
|
| pubmed:articleTitle |
New-onset lymphopenia assessed during routine follow-up is a risk factor for relapse postautologous peripheral blood hematopoietic stem cell transplantation in patients with diffuse large B-cell lymphoma.
|
| pubmed:affiliation |
Division of Hematology/Department of Medicine, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA. porrata.luis@mayo.edu
|
| pubmed:publicationType |
Journal Article
|